Drugs / Praluzatamab Ravtansine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03149549 | Jun 2017 → Sep 2020 | breast cancer, head and neck cancer, non-small cell lung carcinoma, ovarian cancer | CytomX Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT04596150 | Dec 2020 → Jun 2023 | hormone receptor-positive breast cancer, triple-negative breast carcinoma | CytomX Therapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Praluzatamab Ravtansine | “A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX-2009) in Advanced HR-Positive/HER2-Negative Breast Cancer and of...” NCT04596150 ↗ |
| Known as | Anti-cd166-dm4 cx-2009 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297736 ↗ |
| Known as | CX-2009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04596150 ↗ |
| Known as | Praluzatamab ravtansina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297736 ↗ |
| Route | Intravenous | “Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)” NCT04596150 ↗ |
| Target | ALCAM | “CD166 antigen binding agent” CHEMBL4297736 ↗ |